Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Colorectal Neoplasms 22Neoplasms 13Colonic Neoplasms 10Breast Neoplasms 10Venous Thromboembolism 8Prostatic Neoplasms 8Multiple Myeloma 7Recurrence 6Polycythemia Vera 6Carcinoma, Non-Small-Cell Lung 6Thrombocythemia, Essential 4Neoplasms, Plasma Cell 4Ovarian Neoplasms 3Neoplasm Metastasis 3Melanoma 3Thrombosis 2Sarcoma 2Rectal Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Neoplastic Cells, Circulating 2Neoplasms by Site 2Myocardial Infarction 2Lung Neoplasms 2Intestinal Neoplasms 2Intestinal Diseases 2Inflammation 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × Aspirin × Clear all
NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Peter MacCallum Cancer Centre, Australia

Phase 2 Completed
150 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated
63 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01042704 2017-07-31

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

University of Pittsburgh

Phase 1 Completed
29 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡